US consensus guidelines for the use of cyclosporin A in rheumatoid arthritis

John J. Cush, Peter Tugwell, Michael Weinblatt, David Yocum

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease that often leads to irreversible joint damage and loss of function. Although there are numerous treatment options, it is difficult to manage the disease in most patients. Use of cyclosporin A (CsA) for RA was first reported in 1979, and since that time many trials have investigated CsA use for this disease. Based on clinical evidence, CsA is an efficacious second-line agent for patients with active RA who have not responded adequately to methotrexate (MTX). In addition, CsA has been shown to provide clinical benefit when used in combination with MTX in patients responding inadequately to MTX monotherapy. Side effects associated with CsA treatment are manageable if dosing, monitoring, and intervention guidelines are followed. The purpose of this review is to provide recommendations for the use of CsA in severe RA to physicians experienced in the management of systemic immunosuppressive therapy for RA. Where possible and appropriate, recommendations are based on evidence available in the literature.

Original languageEnglish (US)
Pages (from-to)1176-1186
Number of pages11
JournalJournal of Rheumatology
Volume26
Issue number5
StatePublished - Jan 1 1999
Externally publishedYes

Fingerprint

Cyclosporine
Rheumatoid Arthritis
Guidelines
Methotrexate
Proxy
Immunosuppressive Agents
Therapeutics
Joints
Physicians

Keywords

  • Cyclosporine
  • Practice guidelines
  • Review
  • Rheumatoid arthritis
  • United States

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

US consensus guidelines for the use of cyclosporin A in rheumatoid arthritis. / Cush, John J.; Tugwell, Peter; Weinblatt, Michael; Yocum, David.

In: Journal of Rheumatology, Vol. 26, No. 5, 01.01.1999, p. 1176-1186.

Research output: Contribution to journalArticle

Cush, JJ, Tugwell, P, Weinblatt, M & Yocum, D 1999, 'US consensus guidelines for the use of cyclosporin A in rheumatoid arthritis', Journal of Rheumatology, vol. 26, no. 5, pp. 1176-1186.
Cush, John J. ; Tugwell, Peter ; Weinblatt, Michael ; Yocum, David. / US consensus guidelines for the use of cyclosporin A in rheumatoid arthritis. In: Journal of Rheumatology. 1999 ; Vol. 26, No. 5. pp. 1176-1186.
@article{722ecdbe6f0e44a883f6b813c6058f26,
title = "US consensus guidelines for the use of cyclosporin A in rheumatoid arthritis",
abstract = "Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease that often leads to irreversible joint damage and loss of function. Although there are numerous treatment options, it is difficult to manage the disease in most patients. Use of cyclosporin A (CsA) for RA was first reported in 1979, and since that time many trials have investigated CsA use for this disease. Based on clinical evidence, CsA is an efficacious second-line agent for patients with active RA who have not responded adequately to methotrexate (MTX). In addition, CsA has been shown to provide clinical benefit when used in combination with MTX in patients responding inadequately to MTX monotherapy. Side effects associated with CsA treatment are manageable if dosing, monitoring, and intervention guidelines are followed. The purpose of this review is to provide recommendations for the use of CsA in severe RA to physicians experienced in the management of systemic immunosuppressive therapy for RA. Where possible and appropriate, recommendations are based on evidence available in the literature.",
keywords = "Cyclosporine, Practice guidelines, Review, Rheumatoid arthritis, United States",
author = "Cush, {John J.} and Peter Tugwell and Michael Weinblatt and David Yocum",
year = "1999",
month = "1",
day = "1",
language = "English (US)",
volume = "26",
pages = "1176--1186",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "5",

}

TY - JOUR

T1 - US consensus guidelines for the use of cyclosporin A in rheumatoid arthritis

AU - Cush, John J.

AU - Tugwell, Peter

AU - Weinblatt, Michael

AU - Yocum, David

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease that often leads to irreversible joint damage and loss of function. Although there are numerous treatment options, it is difficult to manage the disease in most patients. Use of cyclosporin A (CsA) for RA was first reported in 1979, and since that time many trials have investigated CsA use for this disease. Based on clinical evidence, CsA is an efficacious second-line agent for patients with active RA who have not responded adequately to methotrexate (MTX). In addition, CsA has been shown to provide clinical benefit when used in combination with MTX in patients responding inadequately to MTX monotherapy. Side effects associated with CsA treatment are manageable if dosing, monitoring, and intervention guidelines are followed. The purpose of this review is to provide recommendations for the use of CsA in severe RA to physicians experienced in the management of systemic immunosuppressive therapy for RA. Where possible and appropriate, recommendations are based on evidence available in the literature.

AB - Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease that often leads to irreversible joint damage and loss of function. Although there are numerous treatment options, it is difficult to manage the disease in most patients. Use of cyclosporin A (CsA) for RA was first reported in 1979, and since that time many trials have investigated CsA use for this disease. Based on clinical evidence, CsA is an efficacious second-line agent for patients with active RA who have not responded adequately to methotrexate (MTX). In addition, CsA has been shown to provide clinical benefit when used in combination with MTX in patients responding inadequately to MTX monotherapy. Side effects associated with CsA treatment are manageable if dosing, monitoring, and intervention guidelines are followed. The purpose of this review is to provide recommendations for the use of CsA in severe RA to physicians experienced in the management of systemic immunosuppressive therapy for RA. Where possible and appropriate, recommendations are based on evidence available in the literature.

KW - Cyclosporine

KW - Practice guidelines

KW - Review

KW - Rheumatoid arthritis

KW - United States

UR - http://www.scopus.com/inward/record.url?scp=0032963703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032963703&partnerID=8YFLogxK

M3 - Article

C2 - 10332987

AN - SCOPUS:0032963703

VL - 26

SP - 1176

EP - 1186

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 5

ER -